The US FDA Approves First Supplemental Abbreviated New Drug Application (sANDA) for Glenmark Pharmaceuticals’ Manufacturing Facility in Monroe, North Carolina

The US FDA Approves First Supplemental Abbreviated New Drug Application (sANDA) for Glenmark Pharmaceuticals’ Manufacturing Facility in Monroe, North Carolina

June 18, 2018 sANDA approval is for manufacturing of Atovaquone and Proguanil Hydrochloride Tablets, 250 MG/100 MG AND 62.5 MG/25 MG at Monroe facility PARAMUS, N.J., June 18, 2018 /PRNewswire/ — Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that the U.S.

Glenmark Pharmaceuticals Announces Poster Presentations on GBR 1302 and GBR 1342, HER2xCD3 and CD38xCD3 Bispecific Antibodies, at the 2018 ASCO Annual Meeting

Glenmark Pharmaceuticals Announces Poster Presentations on GBR 1302 and GBR 1342, HER2xCD3 and CD38xCD3 Bispecific Antibodies, at the 2018 ASCO Annual Meeting

PARAMUS, N.J., May 25, 2018 /PRNewswire/ — Glenmark Pharmaceuticals, a global pharmaceutical company, today announced the presentation of data from two assets in its immuno-oncology portfolio at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO). These presentations include preclinical